Florida Senate - 2022 SB 1688
By Senator Gruters
23-01339-22 20221688__
1 A bill to be entitled
2 An act relating to pharmaceutical products containing
3 cannabis; amending s. 893.03, F.S.; excluding cannabis
4 from Schedule I listing if it is contained within a
5 pharmaceutical product approved by the United States
6 Food and Drug Administration; providing an effective
7 date.
8
9 Be It Enacted by the Legislature of the State of Florida:
10
11 Section 1. Paragraph (c) of subsection (1) of section
12 893.03, Florida Statutes, is amended to read:
13 893.03 Standards and schedules.—The substances enumerated
14 in this section are controlled by this chapter. The controlled
15 substances listed or to be listed in Schedules I, II, III, IV,
16 and V are included by whatever official, common, usual,
17 chemical, trade name, or class designated. The provisions of
18 this section shall not be construed to include within any of the
19 schedules contained in this section any excluded drugs listed
20 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
21 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
22 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
23 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
24 Anabolic Steroid Products.”
25 (1) SCHEDULE I.—A substance in Schedule I has a high
26 potential for abuse and has no currently accepted medical use in
27 treatment in the United States and in its use under medical
28 supervision does not meet accepted safety standards. The
29 following substances are controlled in Schedule I:
30 (c) Unless specifically excepted or unless listed in
31 another schedule, any material, compound, mixture, or
32 preparation that contains any quantity of the following
33 hallucinogenic substances or that contains any of their salts,
34 isomers, including optical, positional, or geometric isomers,
35 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
36 salts of isomers, homologues, nitrogen-heterocyclic analogs,
37 esters, or ethers, if the existence of such salts, isomers, and
38 salts of isomers is possible within the specific chemical
39 designation or class description:
40 1. Alpha-Ethyltryptamine.
41 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
42 oxazoline).
43 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
44 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
45 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
46 6. Bufotenine.
47 7. Cannabis, except if it is contained within a
48 pharmaceutical product approved by the United States Food and
49 Drug Administration.
50 8. Cathinone.
51 9. DET (Diethyltryptamine).
52 10. 2,5-Dimethoxyamphetamine.
53 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
54 12. DMT (Dimethyltryptamine).
55 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
56 analog of phencyclidine).
57 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
58 15. N-Ethylamphetamine.
59 16. Fenethylline.
60 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
61 18. Ibogaine.
62 19. LSD (Lysergic acid diethylamide).
63 20. Mescaline.
64 21. Methcathinone.
65 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
66 23. PMA (4-Methoxyamphetamine).
67 24. PMMA (4-Methoxymethamphetamine).
68 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
69 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
70 27. MDA (3,4-Methylenedioxyamphetamine).
71 28. JB-336 (N-Methyl-3-piperidyl benzilate).
72 29. N,N-Dimethylamphetamine.
73 30. Parahexyl.
74 31. Peyote.
75 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
76 analog of phencyclidine).
77 33. Psilocybin.
78 34. Psilocyn.
79 35. Salvia divinorum, except for any drug product approved
80 by the United States Food and Drug Administration which contains
81 Salvia divinorum or its isomers, esters, ethers, salts, and
82 salts of isomers, esters, and ethers, if the existence of such
83 isomers, esters, ethers, and salts is possible within the
84 specific chemical designation.
85 36. Salvinorin A, except for any drug product approved by
86 the United States Food and Drug Administration which contains
87 Salvinorin A or its isomers, esters, ethers, salts, and salts of
88 isomers, esters, and ethers, if the existence of such isomers,
89 esters, ethers, and salts is possible within the specific
90 chemical designation.
91 37. Xylazine.
92 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
93 (Thiophene analog of phencyclidine).
94 39. 3,4,5-Trimethoxyamphetamine.
95 40. Methylone (3,4-Methylenedioxymethcathinone).
96 41. MDPV (3,4-Methylenedioxypyrovalerone).
97 42. Methylmethcathinone.
98 43. Methoxymethcathinone.
99 44. Fluoromethcathinone.
100 45. Methylethcathinone.
101 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
102 yl)phenol) and its dimethyloctyl (C8) homologue.
103 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
104 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
105 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
106 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
107 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
108 naphthoyl)indole).
109 51. BZP (Benzylpiperazine).
110 52. Fluorophenylpiperazine.
111 53. Methylphenylpiperazine.
112 54. Chlorophenylpiperazine.
113 55. Methoxyphenylpiperazine.
114 56. DBZP (1,4-Dibenzylpiperazine).
115 57. TFMPP (Trifluoromethylphenylpiperazine).
116 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
117 Methylenedioxy-N-methylbutanamine).
118 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
119 60. 5-Hydroxy-N-methyltryptamine.
120 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
121 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
122 63. Methyltryptamine.
123 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
124 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
125 66. Tyramine (4-Hydroxyphenethylamine).
126 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
127 68. DiPT (N,N-Diisopropyltryptamine).
128 69. DPT (N,N-Dipropyltryptamine).
129 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
130 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
131 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
132 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
133 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
134 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
135 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
136 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
137 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
138 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
139 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
140 81. Butylone (3,4-Methylenedioxy-alpha
141 methylaminobutyrophenone).
142 82. Ethcathinone.
143 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
144 84. Naphyrone (Naphthylpyrovalerone).
145 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
146 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
147 87. 3,4-Methylenedioxy-propiophenone.
148 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
149 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
150 90. 3,4-Methylenedioxy-N-acetylcathinone.
151 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
152 92. 3,4-Methylenedioxy-N-acetylethcathinone.
153 93. Bromomethcathinone.
154 94. Buphedrone (alpha-Methylamino-butyrophenone).
155 95. Eutylone (3,4-Methylenedioxy-alpha
156 ethylaminobutyrophenone).
157 96. Dimethylcathinone.
158 97. Dimethylmethcathinone.
159 98. Pentylone (3,4-Methylenedioxy-alpha
160 methylaminovalerophenone).
161 99. MDPPP (3,4-Methylenedioxy-alpha
162 pyrrolidinopropiophenone).
163 100. MDPBP (3,4-Methylenedioxy-alpha
164 pyrrolidinobutyrophenone).
165 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
166 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
167 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
168 (Benocyclidine).
169 104. F-MABP (Fluoromethylaminobutyrophenone).
170 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
171 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
172 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
173 108. Me-EABP (Methylethylaminobutyrophenone).
174 109. Etizolam.
175 110. PPP (Pyrrolidinopropiophenone).
176 111. PBP (Pyrrolidinobutyrophenone).
177 112. PVP (Pyrrolidinovalerophenone) or
178 (Pyrrolidinopentiophenone).
179 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
180 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
181 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
182 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
183 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
184 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
185 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
186 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
187 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
188 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
189 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
190 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
191 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
192 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
193 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
194 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
195 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
196 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
197 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
198 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
199 ol).
200 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
201 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
202 methanol).
203 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
204 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
205 1,4-dione).
206 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
207 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
208 undecanamide).
209 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
210 undecanamide).
211 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
212 methyloctan-2-yl)phenol).
213 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
214 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
215 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
216 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
217 methoxyphenylacetyl)indole).
218 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
219 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
220 naphthalenylmethanone).
221 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
222 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
223 naphthalenylmethanone).
224 143. Pentedrone (alpha-Methylaminovalerophenone).
225 144. Fluoroamphetamine.
226 145. Fluoromethamphetamine.
227 146. Methoxetamine.
228 147. Methiopropamine.
229 148. Methylbuphedrone (Methyl-alpha
230 methylaminobutyrophenone).
231 149. APB ((2-Aminopropyl)benzofuran).
232 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
233 151. UR-144 (1-Pentyl-3-(2,2,3,3
234 tetramethylcyclopropanoyl)indole).
235 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
236 tetramethylcyclopropanoyl)indole).
237 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
238 tetramethylcyclopropanoyl)indole).
239 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
240 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
241 iodobenzoyl)indole).
242 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
243 carboxamide).
244 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
245 cyclohexylcarbamate).
246 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
247 cyclohexyl ester).
248 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
249 benzoxazin-4-one).
250 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
251 161. 2C-H (2,5-Dimethoxyphenethylamine).
252 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
253 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
254 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
255 methoxybenzyl)]phenethylamine).
256 165. MDMA (3,4-Methylenedioxymethamphetamine).
257 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
258 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
259 carboxylate).
260 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
261 carboxylate).
262 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
263 3-carboxamide).
264 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
265 pentylindazole-3-carboxamide).
266 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
267 (4-fluorobenzyl)indazole-3-carboxamide).
268 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
269 1-pentylindazole-3-carboxamide).
270 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
271 yl)-1-(fluoropentyl)indole-3-carboxamide).
272 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
273 methoxybenzyl)]phenethylamine).
274 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
275 methoxybenzyl)]phenethylamine).
276 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
277 (cyclohexylmethyl)indazole-3-carboxamide).
278 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
279 carboxylate).
280 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
281 3-carboxamide).
282 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
283 (fluoropentyl)indazole-3-carboxamide).
284 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
285 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
286 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
287 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
288 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
289 hexahydrobenzo[c]chromen-1-ol).
290 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
291 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
292 hexahydrobenzo[c]chromen-1-ol).
293 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
294 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
295 diol).
296 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
297 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
298 tetrahydro-6aH-benzo[c]chromen-1-ol).
299 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
300 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
301 187. MAPB ((2-Methylaminopropyl)benzofuran).
302 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
303 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
304 190. Synthetic Cannabinoids.—Unless specifically excepted
305 or unless listed in another schedule or contained within a
306 pharmaceutical product approved by the United States Food and
307 Drug Administration, any material, compound, mixture, or
308 preparation that contains any quantity of a synthetic
309 cannabinoid found to be in any of the following chemical class
310 descriptions, or homologues, nitrogen-heterocyclic analogs,
311 isomers (including optical, positional, or geometric), esters,
312 ethers, salts, and salts of homologues, nitrogen-heterocyclic
313 analogs, isomers, esters, or ethers, whenever the existence of
314 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
315 ethers, salts, and salts of isomers, esters, or ethers is
316 possible within the specific chemical class or designation.
317 Since nomenclature of these synthetically produced cannabinoids
318 is not internationally standardized and may continually evolve,
319 these structures or the compounds of these structures shall be
320 included under this subparagraph, regardless of their specific
321 numerical designation of atomic positions covered, if it can be
322 determined through a recognized method of scientific testing or
323 analysis that the substance contains properties that fit within
324 one or more of the following categories:
325 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
326 naturally contained in a plant of the genus Cannabis, the
327 synthetic equivalents of the substances contained in the plant
328 or in the resinous extracts of the genus Cannabis, or synthetic
329 substances, derivatives, and their isomers with similar chemical
330 structure and pharmacological activity, including, but not
331 limited to, Delta 9 tetrahydrocannabinols and their optical
332 isomers, Delta 8 tetrahydrocannabinols and their optical
333 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
334 isomers, or any compound containing a tetrahydrobenzo[c]chromene
335 structure with substitution at either or both the 3-position or
336 9-position, with or without substitution at the 1-position with
337 hydroxyl or alkoxy groups, including, but not limited to:
338 (I) Tetrahydrocannabinol.
339 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
340 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
341 ol).
342 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
343 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
344 ol).
345 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
346 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
347 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
348 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
349 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
350 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
351 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
352 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
353 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
354 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
355 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
356 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
357 (X) Parahexyl.
358 b. Naphthoylindoles, Naphthoylindazoles,
359 Naphthoylcarbazoles, Naphthylmethylindoles,
360 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
361 compound containing a naphthoylindole, naphthoylindazole,
362 naphthoylcarbazole, naphthylmethylindole,
363 naphthylmethylindazole, or naphthylmethylcarbazole structure,
364 with or without substitution on the indole, indazole, or
365 carbazole ring to any extent, whether or not substituted on the
366 naphthyl ring to any extent, including, but not limited to:
367 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
368 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
369 naphthoyl)indole).
370 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
371 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
372 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
373 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
374 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
375 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
376 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
377 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
378 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
379 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
380 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
381 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
382 naphthoyl)indole).
383 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
384 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
385 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
386 naphthoyl)indole).
387 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
388 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
389 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
390 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
391 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
392 naphthylmethyl]indole).
393 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
394 naphthoyl)indole).
395 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
396 naphthoyl)indole).
397 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
398 naphthoyl)indole).
399 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
400 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
401 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
402 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
403 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
404 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
405 naphthoyl)indole).
406 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
407 naphthoyl)indole).
408 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
409 naphthoyl)indole).
410 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
411 naphthoyl)indole).
412 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
413 naphthoyl)indole).
414 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
415 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
416 naphthoyl)indazole).
417 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
418 naphthoyl)indole).
419 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
420 naphthoyl)indole).
421 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
422 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
423 naphthoyl)carbazole).
424 c. Naphthoylpyrroles.—Any compound containing a
425 naphthoylpyrrole structure, with or without substitution on the
426 pyrrole ring to any extent, whether or not substituted on the
427 naphthyl ring to any extent, including, but not limited to:
428 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
429 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
430 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
431 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
432 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
433 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
434 naphthoyl)pyrrole).
435 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
436 naphthoyl)pyrrole).
437 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
438 naphthoyl)pyrrole).
439 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
440 naphthoyl)pyrrole).
441 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
442 naphthoyl)pyrrole).
443 d. Naphthylmethylenindenes.—Any compound containing a
444 naphthylmethylenindene structure, with or without substitution
445 at the 3-position of the indene ring to any extent, whether or
446 not substituted on the naphthyl ring to any extent, including,
447 but not limited to, JWH-176 (3-Pentyl-1
448 (naphthylmethylene)indene).
449 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
450 compound containing a phenylacetylindole or phenylacetylindazole
451 structure, with or without substitution on the indole or
452 indazole ring to any extent, whether or not substituted on the
453 phenyl ring to any extent, including, but not limited to:
454 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
455 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
456 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
457 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
458 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
459 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
460 (VII) Cannabipiperidiethanone.
461 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
462 methoxyphenylacetyl)indole).
463 f. Cyclohexylphenols.—Any compound containing a
464 cyclohexylphenol structure, with or without substitution at the
465 5-position of the phenolic ring to any extent, whether or not
466 substituted on the cyclohexyl ring to any extent, including, but
467 not limited to:
468 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
469 yl)phenol).
470 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
471 homologue).
472 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
473 methyloctan-2-yl)phenol).
474 g. Benzoylindoles and Benzoylindazoles.—Any compound
475 containing a benzoylindole or benzoylindazole structure, with or
476 without substitution on the indole or indazole ring to any
477 extent, whether or not substituted on the phenyl ring to any
478 extent, including, but not limited to:
479 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
480 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
481 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
482 iodo-5-nitrobenzoyl)indole).
483 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
484 methoxybenzoyl)indole).
485 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
486 iodobenzoyl)indole).
487 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
488 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
489 methoxybenzoyl)indole).
490 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
491 3-(4-methoxybenzoyl)indole).
492 h. Tetramethylcyclopropanoylindoles and
493 Tetramethylcyclopropanoylindazoles.—Any compound containing a
494 tetramethylcyclopropanoylindole or
495 tetramethylcyclopropanoylindazole structure, with or without
496 substitution on the indole or indazole ring to any extent,
497 whether or not substituted on the tetramethylcyclopropyl group
498 to any extent, including, but not limited to:
499 (I) UR-144 (1-Pentyl-3-(2,2,3,3
500 tetramethylcyclopropanoyl)indole).
501 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
502 tetramethylcyclopropanoyl)indole).
503 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
504 tetramethylcyclopropanoyl)indole).
505 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
506 tetramethylcyclopropanoyl)indole).
507 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
508 tetramethylcyclopropanoyl)indole).
509 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
510 tetramethylcyclopropanoyl)indole).
511 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
512 tetramethylcyclopropanoyl)indole).
513 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
514 tetramethylcyclopropanoyl)indazole).
515 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
516 tetramethylcyclopropanoyl)indole).
517 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
518 tetramethylcyclopropanoyl)indole).
519 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
520 carboxamides, and Adamantylindazole carboxamides.—Any compound
521 containing an adamantoyl indole, adamantoyl indazole, adamantyl
522 indole carboxamide, or adamantyl indazole carboxamide structure,
523 with or without substitution on the indole or indazole ring to
524 any extent, whether or not substituted on the adamantyl ring to
525 any extent, including, but not limited to:
526 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
527 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
528 3-carboxamide).
529 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
530 carboxamide).
531 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
532 adamantoyl)indole).
533 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
534 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
535 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
536 adamantoyl)indole).
537 j. Quinolinylindolecarboxylates,
538 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
539 and Quinolinylindazolecarboxamides.—Any compound containing a
540 quinolinylindole carboxylate, quinolinylindazole carboxylate,
541 isoquinolinylindole carboxylate, isoquinolinylindazole
542 carboxylate, quinolinylindole carboxamide, quinolinylindazole
543 carboxamide, isoquinolinylindole carboxamide, or
544 isoquinolinylindazole carboxamide structure, with or without
545 substitution on the indole or indazole ring to any extent,
546 whether or not substituted on the quinoline or isoquinoline ring
547 to any extent, including, but not limited to:
548 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
549 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
550 carboxylate).
551 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
552 carboxylate).
553 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
554 carboxylate).
555 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
556 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
557 3-carboxylate).
558 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
559 3-carboxylate).
560 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
561 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
562 carboxamide).
563 k. Naphthylindolecarboxylates and
564 Naphthylindazolecarboxylates.—Any compound containing a
565 naphthylindole carboxylate or naphthylindazole carboxylate
566 structure, with or without substitution on the indole or
567 indazole ring to any extent, whether or not substituted on the
568 naphthyl ring to any extent, including, but not limited to:
569 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
570 carboxylate).
571 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
572 carboxylate).
573 (III) Fluoro SDB-005 (1-Naphthalenyl 1
574 (fluoropentyl)indazole-3-carboxylate).
575 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
576 carboxylate).
577 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
578 carboxylate).
579 l. Naphthylindole carboxamides and Naphthylindazole
580 carboxamides.—Any compound containing a naphthylindole
581 carboxamide or naphthylindazole carboxamide structure, with or
582 without substitution on the indole or indazole ring to any
583 extent, whether or not substituted on the naphthyl ring to any
584 extent, including, but not limited to:
585 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
586 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
587 3-carboxamide).
588 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
589 (chloropentyl)indole-3-carboxamide).
590 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
591 carboxamide).
592 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
593 (fluoropentyl)indazole-3-carboxamide).
594 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
595 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
596 Alkylcarbonyl indazole carboxylates.—Any compound containing an
597 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
598 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
599 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
600 indole carboxamide, indazole carboxamide, indole carboxylate, or
601 indazole carboxylate, with or without substitution on the indole
602 or indazole ring to any extent, whether or not substituted on
603 the alkylcarbonyl group to any extent, including, but not
604 limited to:
605 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
606 pentylindole-3-carboxamide).
607 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
608 yl)-1-(fluoropentyl)indole-3-carboxamide).
609 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
610 (fluoropentyl)indole-3-carboxamide).
611 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
612 pentylindazole-3-carboxamide).
613 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
614 1-(fluoropentyl)indazole-3-carboxamide).
615 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
616 1-pentylindazole-3-carboxamide).
617 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
618 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
619 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
620 (4-fluorobenzyl)indazole-3-carboxamide).
621 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
622 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
623 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
624 (cyclohexylmethyl)indazole-3-carboxamide).
625 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
626 (cyclohexylmethyl)indazole-3-carboxamide).
627 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
628 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
629 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
630 pentylindazole-3-carboxamide).
631 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
632 (fluoropentyl)indazole-3-carboxamide).
633 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
634 fluorobenzyl)indazole-3-carboxamide).
635 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
636 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
637 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
638 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
639 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
640 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
641 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
642 fluoropentyl)indole-3-carboxamide).
643 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
644 fluoropentyl)indazole-3-carboxamide).
645 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
646 (cyclohexylmethyl)indazole-3-carboxamide).
647 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
648 fluorobenzyl)indazole-3-carboxamide).
649 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
650 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
651 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
652 Any compound containing a N-(2-phenylpropan-2-yl) indole
653 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
654 structure, with or without substitution on the indole or
655 indazole ring to any extent, whether or not substituted on the
656 phenyl ring of the cumyl group to any extent, including, but not
657 limited to:
658 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
659 carboxamide).
660 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
661 (fluoropentyl)indole-3-carboxamide).
662 o. Other Synthetic Cannabinoids.—Any material, compound,
663 mixture, or preparation that contains any quantity of a
664 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
665 (I) With or without modification or replacement of a
666 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
667 between either two core rings, or linkage between a core ring
668 and group structure, with or without the addition of a carbon or
669 replacement of a carbon;
670 (II) With or without replacement of a core ring or group
671 structure, whether or not substituted on the ring or group
672 structures to any extent; and
673 (III) Is a cannabinoid receptor agonist, unless
674 specifically excepted or unless listed in another schedule or
675 contained within a pharmaceutical product approved by the United
676 States Food and Drug Administration.
677 191. Substituted Cathinones.—Unless specifically excepted,
678 listed in another schedule, or contained within a pharmaceutical
679 product approved by the United States Food and Drug
680 Administration, any material, compound, mixture, or preparation,
681 including its salts, isomers, esters, or ethers, and salts of
682 isomers, esters, or ethers, whenever the existence of such salts
683 is possible within any of the following specific chemical
684 designations:
685 a. Any compound containing a 2-amino-1-phenyl-1-propanone
686 structure;
687 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
688 structure; or
689 c. Any compound containing a 2-amino-1-thiophenyl-1
690 propanone structure,
691
692 whether or not the compound is further modified:
693 (I) With or without substitution on the ring system to any
694 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
695 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
696 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
697 substituents;
698 (II) With or without substitution at the 3-propanone
699 position with an alkyl substituent or removal of the methyl
700 group at the 3-propanone position;
701 (III) With or without substitution at the 2-amino nitrogen
702 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
703 not further substituted in the ring system; or
704 (IV) With or without inclusion of the 2-amino nitrogen atom
705 in a cyclic structure, including, but not limited to:
706 (A) Methcathinone.
707 (B) Ethcathinone.
708 (C) Methylone (3,4-Methylenedioxymethcathinone).
709 (D) 2,3-Methylenedioxymethcathinone.
710 (E) MDPV (3,4-Methylenedioxypyrovalerone).
711 (F) Methylmethcathinone.
712 (G) Methoxymethcathinone.
713 (H) Fluoromethcathinone.
714 (I) Methylethcathinone.
715 (J) Butylone (3,4-Methylenedioxy-alpha
716 methylaminobutyrophenone).
717 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
718 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
719 (M) Naphyrone (Naphthylpyrovalerone).
720 (N) Bromomethcathinone.
721 (O) Buphedrone (alpha-Methylaminobutyrophenone).
722 (P) Eutylone (3,4-Methylenedioxy-alpha
723 ethylaminobutyrophenone).
724 (Q) Dimethylcathinone.
725 (R) Dimethylmethcathinone.
726 (S) Pentylone (3,4-Methylenedioxy-alpha
727 methylaminovalerophenone).
728 (T) Pentedrone (alpha-Methylaminovalerophenone).
729 (U) MDPPP (3,4-Methylenedioxy-alpha
730 pyrrolidinopropiophenone).
731 (V) MDPBP (3,4-Methylenedioxy-alpha
732 pyrrolidinobutyrophenone).
733 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
734 (X) PPP (Pyrrolidinopropiophenone).
735 (Y) PVP (Pyrrolidinovalerophenone) or
736 (Pyrrolidinopentiophenone).
737 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
738 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
739 (BB) F-MABP (Fluoromethylaminobutyrophenone).
740 (CC) Me-EABP (Methylethylaminobutyrophenone).
741 (DD) PBP (Pyrrolidinobutyrophenone).
742 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
743 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
744 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
745 (HH) Dimethylone (3,4-Methylenedioxy-N,N
746 dimethylcathinone).
747 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
748 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
749 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
750 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
751 (MM) Methylbuphedrone (Methyl-alpha
752 methylaminobutyrophenone).
753 (NN) Methyl-alpha-methylaminohexanophenone.
754 (OO) N-Ethyl-N-methylcathinone.
755 (PP) PHP (Pyrrolidinohexanophenone).
756 (QQ) PV8 (Pyrrolidinoheptanophenone).
757 (RR) Chloromethcathinone.
758 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
759 192. Substituted Phenethylamines.—Unless specifically
760 excepted or unless listed in another schedule, or contained
761 within a pharmaceutical product approved by the United States
762 Food and Drug Administration, any material, compound, mixture,
763 or preparation, including its salts, isomers, esters, or ethers,
764 and salts of isomers, esters, or ethers, whenever the existence
765 of such salts is possible within any of the following specific
766 chemical designations, any compound containing a phenethylamine
767 structure, without a beta-keto group, and without a benzyl group
768 attached to the amine group, whether or not the compound is
769 further modified with or without substitution on the phenyl ring
770 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
771 halide, fused alkylenedioxy, fused furan, fused benzofuran,
772 fused dihydrofuran, or fused tetrahydropyran substituents,
773 whether or not further substituted on a ring to any extent, with
774 or without substitution at the alpha or beta position by any
775 alkyl substituent, with or without substitution at the nitrogen
776 atom, and with or without inclusion of the 2-amino nitrogen atom
777 in a cyclic structure, including, but not limited to:
778 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
779 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
780 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
781 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
782 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
783 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
784 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
785 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
786 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
787 j. 2C-H (2,5-Dimethoxyphenethylamine).
788 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
789 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
790 m. MDMA (3,4-Methylenedioxymethamphetamine).
791 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
792 Methylenedioxy-N-methylbutanamine).
793 o. MDA (3,4-Methylenedioxyamphetamine).
794 p. 2,5-Dimethoxyamphetamine.
795 q. Fluoroamphetamine.
796 r. Fluoromethamphetamine.
797 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
798 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
799 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
800 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
801 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
802 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
803 y. PMA (4-Methoxyamphetamine).
804 z. N-Ethylamphetamine.
805 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
806 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
807 cc. PMMA (4-Methoxymethamphetamine).
808 dd. N,N-Dimethylamphetamine.
809 ee. 3,4,5-Trimethoxyamphetamine.
810 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
811 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
812 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
813 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
814 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
815 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
816 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
817 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
818 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
819 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
820 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
821 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
822 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
823 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
824 dihydrobenzofuran),
825
826 which does not include phenethylamine, mescaline as described in
827 subparagraph 20., substituted cathinones as described in
828 subparagraph 191., N-Benzyl phenethylamine compounds as
829 described in subparagraph 193., or methamphetamine as described
830 in subparagraph (2)(c)5.
831 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
832 excepted or unless listed in another schedule, or contained
833 within a pharmaceutical product approved by the United States
834 Food and Drug Administration, any material, compound, mixture,
835 or preparation, including its salts, isomers, esters, or ethers,
836 and salts of isomers, esters, or ethers, whenever the existence
837 of such salts is possible within any of the following specific
838 chemical designations, any compound containing a phenethylamine
839 structure without a beta-keto group, with substitution on the
840 nitrogen atom of the amino group with a benzyl substituent, with
841 or without substitution on the phenyl or benzyl ring to any
842 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
843 alkylenedioxy, fused furan, fused benzofuran, or fused
844 tetrahydropyran substituents, whether or not further substituted
845 on a ring to any extent, with or without substitution at the
846 alpha position by any alkyl substituent, including, but not
847 limited to:
848 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
849 methoxybenzyl)]phenethylamine).
850 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
851 hydroxybenzyl)]phenethylamine).
852 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
853 fluorobenzyl)]phenethylamine).
854 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
855 methylenedioxybenzyl)]phenethylamine).
856 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
857 methoxybenzyl)]phenethylamine).
858 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
859 hydroxybenzyl)]phenethylamine).
860 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
861 fluorobenzyl)]phenethylamine).
862 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
863 methylenedioxybenzyl)]phenethylamine).
864 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
865 methoxybenzyl)]phenethylamine).
866 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
867 methoxybenzyl)]phenethylamine).
868 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
869 methoxybenzyl)]phenethylamine).
870 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
871 methoxybenzyl)]phenethylamine).
872 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
873 hydroxybenzyl)]phenethylamine).
874 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
875 fluorobenzyl)]phenethylamine).
876 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
877 methylenedioxybenzyl)]phenethylamine).
878 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
879 methoxybenzyl)]phenethylamine).
880 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
881 hydroxybenzyl)]phenethylamine).
882 r. 25H-NBF (2,5-Dimethoxy-[N-(2
883 fluorobenzyl)]phenethylamine).
884 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
885 methoxybenzyl)]phenethylamine),
886
887 which does not include substituted cathinones as described in
888 subparagraph 191.
889 194. Substituted Tryptamines.—Unless specifically excepted
890 or unless listed in another schedule, or contained within a
891 pharmaceutical product approved by the United States Food and
892 Drug Administration, any material, compound, mixture, or
893 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
894 example tryptamine, structure with or without mono- or di
895 substitution of the amine nitrogen with alkyl or alkenyl groups,
896 or by inclusion of the amino nitrogen atom in a cyclic
897 structure, whether or not substituted at the alpha position with
898 an alkyl group, whether or not substituted on the indole ring to
899 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
900 groups, including, but not limited to:
901 a. Alpha-Ethyltryptamine.
902 b. Bufotenine.
903 c. DET (Diethyltryptamine).
904 d. DMT (Dimethyltryptamine).
905 e. MET (N-Methyl-N-ethyltryptamine).
906 f. DALT (N,N-Diallyltryptamine).
907 g. EiPT (N-Ethyl-N-isopropyltryptamine).
908 h. MiPT (N-Methyl-N-isopropyltryptamine).
909 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
910 j. 5-Hydroxy-N-methyltryptamine.
911 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
912 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
913 m. Methyltryptamine.
914 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
915 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
916 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
917 q. DiPT (N,N-Diisopropyltryptamine).
918 r. DPT (N,N-Dipropyltryptamine).
919 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
920 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
921 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
922 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
923 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
924 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
925 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
926 isopropyltryptamine).
927 z. Methyl-alpha-ethyltryptamine.
928 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
929
930 which does not include tryptamine, psilocyn as described in
931 subparagraph 34., or psilocybin as described in subparagraph 33.
932 195. Substituted Phenylcyclohexylamines.—Unless
933 specifically excepted or unless listed in another schedule, or
934 contained within a pharmaceutical product approved by the United
935 States Food and Drug Administration, any material, compound,
936 mixture, or preparation containing a phenylcyclohexylamine
937 structure, with or without any substitution on the phenyl ring,
938 any substitution on the cyclohexyl ring, any replacement of the
939 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
940 without substitution on the amine with alkyl, dialkyl, or alkoxy
941 substituents, inclusion of the nitrogen in a cyclic structure,
942 or any combination of the above, including, but not limited to:
943 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
944 (Benocyclidine).
945 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
946 of phencyclidine).
947 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
948 analog of phencyclidine).
949 d. PCPr (Phenylcyclohexylpropylamine).
950 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
951 analog of phencyclidine).
952 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
953 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
954 h. Methoxetamine.
955 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
956 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
957 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
958 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
959 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
960 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
961 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
962 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
963 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
964 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
965 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2
966 piperidinylidene]-benzenesulfonamide.
967 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2
968 piperidinylidene]-benzenesulfonamide.
969 198. AH-7921, 3,4-dichloro-N-[[1
970 (dimethylamino)cyclohexyl]methyl]-benzamide.
971 199. U47700, trans-3,4-dichloro-N-[2
972 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
973 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
974 dihydrochloride.
975 Section 2. This act shall take effect upon becoming a law.